Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines, Inc. (RVMD)
:RVMD
Rmc-6236, Tng462, Rmc-9805
Pancreatic Cancer Metastatic, Lung Cancer, Nsclc, Pdac, Pdac - Pancreatic Ductal Adenocarcinoma, Ras Mutation, Mtap Deletion, Thoracic Cancer
Phase I/II
Recruiting
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Mar 28, 2025
―
Docetaxel, Daraxonrasib
Non-small Cell Lung Cancer, Nsclc, Nsclc (Non-Small Cell Lung Cancer), Nsclc (Advanced Non-Small Cell Lung Cancer), Nsclc (Non-Small Cell Lung Carcinoma)
Phase III
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Mar 10, 2025
―
Gemcitabine, Nab-paclitaxel, Oxaliplatin, Irinotecan, Rmc-6236, Leucovorin, 5-Fluorouracil, Liposomal Irinotecan
Pancreatic Cancer, Pdac, Pdac - Pancreatic Ductal Adenocarcinoma
Phase III
Recruiting
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Sep 20, 2024
―
Gemcitabine, Bevacizumab, Nab-paclitaxel, Rmc-6236, Cetuximab, Rmc-9805, Mfolfox6 Regimen, Mfolfirinox Regimen
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Pdac, Crc, Gastrointestinal Cancer
Phase I/II
Recruiting
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
May 20, 2024
―
Pembrolizumab, Rmc-6291, Pemetrexed, Rmc-6236, Carboplatin, Cisplatin, Rmc-9805
Non-Small Cell Lung Cancer, Nsclc, Kras, Nras, Hras-Mutated Nsclc, Kras G12c-Mutated Solid Tumors, Lung Cancer, Lung Cancer Stage Iv, Advanced Solid Tumor, Cancer, Ras G12d-Mutated Nsclc
Phase I/II
Recruiting
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Nov 30, 2023
―
Assigned Interventions
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer (Nsclc)
Phase I
Recruiting
Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors
Nov 07, 2023
―
Rmc-6236, Rmc-9805
Non-Small Cell Lung Cancer (Nsclc), Colorectal Cancer (Crc), Advanced Solid Tumors, Pancreatic Ductal Adenocarcinoma (Pdac)
Phase I
Recruiting
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Aug 31, 2023
―
Rmc-6291
Advanced Solid Tumor, Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer (Nsclc), Colorectal Cancer (Crc)
Phase I
Active Not Recruiting
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Jul 11, 2022
―
Rmc-6236
Non-Small Cell Lung Cancer (Nsclc), Colorectal Cancer (Crc), Advanced Solid Tumors, Pancreatic Ductal Adenocarcinoma (Pdac)
Phase I
Recruiting
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
May 13, 2022
―
Rmc-5552
Solid Tumors
Phase I
Completed
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Feb 25, 2021
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Revolution Medicines, Inc. (RVMD) have in its pipeline
RVMD is currently developing the following drugs: Rmc-6236, Tng462, Rmc-9805, Docetaxel, Daraxonrasib, Gemcitabine, Nab-paclitaxel, Oxaliplatin, Irinotecan, Rmc-6236, Leucovorin, 5-Fluorouracil, Liposomal Irinotecan. These drug candidates are in various stages of clinical development as the company works toward FDA approval.